CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells... These cells are then able to differentiate into bone, cartilage, and adipose tissue.
- Mechanism
- Curator reviewed
CYP-001 is a mesenchymal stem cell (MSC) product that is created from induced pluripotent stem cells. It was developed to treat steroid-resistant acute graft-versus-host disease (GvHD), and for preclinical models of asthma, limb ischemia, cytokine release syndrome, among others. As a regenerative medicine, CYP-001 is being used as a therapeutic to treat patients with COVID-19.
- Also known as
- Mesenchymoangioblast-derived mesenchymal stem cells
- Code names
- CYP-001
What you can answer from here — as of April 23, 2025
Which companies are running trials of CYP-001, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account